دورية أكاديمية
Tobacco-induced hyperglycemia promotes lung cancer progression via cancer cell-macrophage interaction through paracrine IGF2/IR/NPM1-driven PD-L1 expression.
العنوان: | Tobacco-induced hyperglycemia promotes lung cancer progression via cancer cell-macrophage interaction through paracrine IGF2/IR/NPM1-driven PD-L1 expression. |
---|---|
المؤلفون: | Jang HJ; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea., Min HY; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea., Kang YP; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Boo HJ; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; Department of Histology, College of Medicine, Jeju National University, Jeju, 63243, Republic of Korea., Kim J; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea., Ahn JH; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea.; Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea., Oh SH; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea., Jung JH; PET core, Convergence Medicine Research Center, Asan Medical Center, Seoul, 05505, Republic of Korea., Park CS; Soonchunhyang University Bucheon Hospital, Bucheon-si, Gyeonggi-do, 14584, Republic of Korea., Park JS; Soonchunhyang University Bucheon Hospital, Bucheon-si, Gyeonggi-do, 14584, Republic of Korea., Kim SY; PET core, Convergence Medicine Research Center, Asan Medical Center, Seoul, 05505, Republic of Korea.; Department of Convergence Medicine, University of Ulsan College of Medicine, Seoul, 05505, Republic of Korea., Lee HY; Creative Research Initiative Center for concurrent control of emphysema and lung cancer, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr.; Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr.; College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, 08826, Republic of Korea. hylee135@snu.ac.kr. |
المصدر: | Nature communications [Nat Commun] 2024 Jun 08; Vol. 15 (1), pp. 4909. Date of Electronic Publication: 2024 Jun 08. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [London] : Nature Pub. Group |
مواضيع طبية MeSH: | Lung Neoplasms*/metabolism , Lung Neoplasms*/pathology , Lung Neoplasms*/genetics , Mice, Inbred C57BL* , Receptor, Insulin*/metabolism , Receptor, Insulin*/genetics , B7-H1 Antigen*/metabolism , B7-H1 Antigen*/genetics , Hyperglycemia*/metabolism , Benzo(a)pyrene*/toxicity , Nucleophosmin* , Insulin-Like Growth Factor II*/metabolism , Insulin-Like Growth Factor II*/genetics , Disease Progression* , Nuclear Proteins*/metabolism , Nuclear Proteins*/genetics, Animals ; Male ; Humans ; Mice ; Nitrosamines/toxicity ; Tumor-Associated Macrophages/metabolism ; Cell Line, Tumor ; Paracrine Communication ; Gene Expression Regulation, Neoplastic ; Smoking/adverse effects ; Macrophages/metabolism |
مستخلص: | Tobacco smoking (TS) is implicated in lung cancer (LC) progression through the development of metabolic syndrome. However, direct evidence linking metabolic syndrome to TS-mediated LC progression remains to be established. Our findings demonstrate that 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene (NNK and BaP; NB), components of tobacco smoke, induce metabolic syndrome characteristics, particularly hyperglycemia, promoting lung cancer progression in male C57BL/6 J mice. NB enhances glucose uptake in tumor-associated macrophages by increasing the expression and surface localization of glucose transporter (GLUT) 1 and 3, thereby leading to transcriptional upregulation of insulin-like growth factor 2 (IGF2), which subsequently activates insulin receptor (IR) in LC cells in a paracrine manner, promoting its nuclear import. Nuclear IR binds to nucleophosmin (NPM1), resulting in IR/NPM1-mediated activation of the CD274 promoter and expression of programmed death ligand-1 (PD-L1). Restricting glycolysis, depleting macrophages, or blocking PD-L1 inhibits NB-mediated LC progression. Analysis of patient tissues and public databases reveals elevated levels of IGF2 and GLUT1 in tumor-associated macrophages, as well as tumoral PD-L1 and phosphorylated insulin-like growth factor 1 receptor/insulin receptor (pIGF-1R/IR) expression, suggesting potential poor prognostic biomarkers for LC patients. Our data indicate that paracrine IGF2/IR/NPM1/PD-L1 signaling, facilitated by NB-induced dysregulation of glucose levels and metabolic reprogramming of macrophages, contributes to TS-mediated LC progression. (© 2024. The Author(s).) |
References: | J Immunol Methods. 2009 Aug 15;347(1-2):70-8. (PMID: 19567251) Cancers (Basel). 2015 Sep 03;7(3):1758-84. (PMID: 26404379) Immunity. 2016 Oct 18;45(4):817-830. (PMID: 27760338) Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613. (PMID: 30476243) Br J Cancer. 1999 Mar;79(7-8):1121-6. (PMID: 10098745) PLoS One. 2015 May 29;10(5):e0128274. (PMID: 26023930) Cell Metab. 2019 Jun 4;29(6):1363-1375.e8. (PMID: 30745181) Ann Oncol. 2017 Apr 1;28(4):733-740. (PMID: 28200038) BMC Med. 2011 May 05;9:48. (PMID: 21542944) Cancer Res. 2019 Sep 15;79(18):4557-4566. (PMID: 31350295) Cell. 2019 Apr 18;177(3):722-736.e22. (PMID: 30955890) Cancers (Basel). 2019 Sep 19;11(9):. (PMID: 31546918) IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt F):9-562. (PMID: 23189753) Pancreas. 2017 Feb;46(2):237-243. (PMID: 27846134) Diabetes Metab J. 2014 Oct;38(5):330-6. (PMID: 25349819) Front Oncol. 2018 Jul 24;8:267. (PMID: 30087852) Eur J Cancer. 2008 Jan;44(2):293-7. (PMID: 18055193) Methods Mol Biol. 2019;1978:301-321. (PMID: 31119671) Nutrients. 2020 Mar 20;12(3):. (PMID: 32244932) Endocr Rev. 2008 Dec;29(7):777-822. (PMID: 18971485) Sci Rep. 2016 Jun 17;6:28178. (PMID: 27312339) DNA Cell Biol. 2020 Apr;39(4):631-644. (PMID: 32096653) Front Oncol. 2021 Feb 23;11:620993. (PMID: 33708630) Int J Mol Sci. 2020 Nov 17;21(22):. (PMID: 33212987) Cancer Res. 1989 Oct 1;49(19):5305-11. (PMID: 2670201) Cell Metab. 2021 Jan 5;33(1):174-189.e7. (PMID: 33357455) Trends Immunol. 2022 Jul;43(7):546-563. (PMID: 35690521) iScience. 2023 Dec 07;27(1):108653. (PMID: 38274405) Sci Transl Med. 2012 Mar 28;4(127):127ra37. (PMID: 22461641) Nat Rev Cancer. 2003 Oct;3(10):733-44. (PMID: 14570033) Nat Rev Cancer. 2006 Jul;6(7):493-505. (PMID: 16794633) Sci Rep. 2022 Feb 15;12(1):2491. (PMID: 35169172) Diabetes Care. 2012 Nov;35(11):2402-11. (PMID: 23093685) Pathol Res Pract. 2000;196(12):835-40. (PMID: 11156325) Cell. 2018 Jan 11;172(1-2):135-146.e9. (PMID: 29328908) Int J Mol Sci. 2018 Nov 16;19(11):. (PMID: 30453495) Immunotherapy. 2020 Dec;12(18):1313-1324. (PMID: 33012209) IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt E):1-538. (PMID: 23193840) J Occup Environ Med. 2019 Dec;61 Suppl 12:S73-S81. (PMID: 31800453) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) PLoS One. 2017 Jun 1;12(6):e0178885. (PMID: 28570711) Front Immunol. 2019 Jul 03;10:1462. (PMID: 31333642) Cell Metab. 2018 Oct 2;28(4):656-666.e1. (PMID: 30017358) Nat Commun. 2020 Apr 3;11(1):1669. (PMID: 32245950) Cancer Res. 2016 Mar 1;76(5):1031-43. (PMID: 26676749) J Thorac Cardiovasc Surg. 2018 Jan;155(1):356-359. (PMID: 29061464) Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998) Toxicology. 1989 Mar;54(3):241-71. (PMID: 2650016) BMC Public Health. 2017 Oct 10;17(1):797. (PMID: 29017534) Cancer Res. 2016 Nov 15;76(22):6607-6619. (PMID: 27651310) Clin Cancer Res. 2022 May 2;28(9):1821-1831. (PMID: 35191466) Nat Rev Cancer. 2012 Feb 16;12(3):159-69. (PMID: 22337149) Mol Pharmacol. 2013 Sep;84(3):304-13. (PMID: 23761301) Nutrients. 2021 Jul 29;13(8):. (PMID: 34444784) Chin Med J (Engl). 2013;126(19):3668-74. (PMID: 24112161) Arch Med Sci. 2022 Aug 30;18(5):1133-1156. (PMID: 36160355) Carcinogenesis. 1994 Dec;15(12):2721-5. (PMID: 8001227) Dis Model Mech. 2010 Sep-Oct;3(9-10):525-34. (PMID: 20713647) PLoS One. 2016 Dec 19;11(12):e0168797. (PMID: 27992582) Cell Mol Gastroenterol Hepatol. 2019;7(2):447-456. (PMID: 30739869) Front Immunol. 2021 Jun 29;12:702580. (PMID: 34267763) Oncotarget. 2016 Jul 12;7(28):44821-44840. (PMID: 27058426) Cancer Lett. 2018 Apr 10;419:187-202. (PMID: 29331414) Eur J Cancer. 2013 Jul;49(10):2411-23. (PMID: 23562551) Front Oncol. 2018 Sep 19;8:386. (PMID: 30283733) EMBO Mol Med. 2022 Jun 8;14(6):e14283. (PMID: 35506376) Cancer. 2014 Dec 1;120(23):3617-26. (PMID: 25043526) Br J Cancer. 2022 Jun;126(11):1637-1646. (PMID: 35194190) J Hematol Oncol. 2019 Jul 12;12(1):76. (PMID: 31300030) Cell Commun Signal. 2020 Apr 7;18(1):59. (PMID: 32264958) Bio Protoc. 2018 Oct 05;8(19):e3035. (PMID: 34532513) Methods Mol Biol. 2015;1339:247-54. (PMID: 26445794) Sci Adv. 2020 Sep 18;6(38):. (PMID: 32948597) J Oncol. 2011;2011:654931. (PMID: 21559255) Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552. (PMID: 34723319) Immunity. 2014 Jul 17;41(1):49-61. (PMID: 25035953) Biochim Biophys Acta Mol Cell Res. 2018 Apr;1865(4):551-559. (PMID: 29317261) PLoS One. 2022 Oct 14;17(10):e0275874. (PMID: 36240258) Br J Cancer. 2006 Aug 7;95(3):272-81. (PMID: 16832418) Cancer Immunol Res. 2022 Feb;10(2):146-153. (PMID: 34937730) Int J Oncol. 2011 Nov;39(5):1193-8. (PMID: 21822536) Cell. 2016 Oct 6;167(2):457-470.e13. (PMID: 27667687) Nat Rev Immunol. 2019 Jun;19(6):369-382. (PMID: 30718830) Cancer Metab. 2014 Jul 29;2:11. (PMID: 25097756) |
معلومات مُعتمدة: | NRF-2016R1A3B1908631 National Research Foundation (NRF) |
المشرفين على المادة: | EC 2.7.10.1 (Receptor, Insulin) 0 (B7-H1 Antigen) 3417WMA06D (Benzo(a)pyrene) 117896-08-9 (Nucleophosmin) 67763-97-7 (Insulin-Like Growth Factor II) 0 (Nuclear Proteins) 0 (Npm1 protein, mouse) 0 (Nitrosamines) 0 (NPM1 protein, human) 0 (IGF2 protein, mouse) 0 (Cd274 protein, mouse) 0 (CD274 protein, human) 0 (IGF2 protein, human) |
تواريخ الأحداث: | Date Created: 20240608 Date Completed: 20240608 Latest Revision: 20240611 |
رمز التحديث: | 20240611 |
مُعرف محوري في PubMed: | PMC11162468 |
DOI: | 10.1038/s41467-024-49199-9 |
PMID: | 38851766 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2041-1723 |
---|---|
DOI: | 10.1038/s41467-024-49199-9 |